Current progress in pharmacologic treatment strategies for alcohol dependence (Q38040129)

27 August 2017

title

Current progress in pharmacologic treatment strategies for alcohol dependence (English)

1 reference

27 August 2017

Peter Clapp

1 reference

27 August 2017

language of work or name

English

0 references

publication date

1 July 2012

1 reference

Expert Review of Clinical Pharmacology

27 August 2017

published in

1 reference

27 August 2017

1 reference

27 August 2017

1 reference

27 August 2017

page(s)

427-435

1 reference

The role of GABA(A) receptors in the acute and chronic effects of ethanol

27 August 2017

cites work

1 reference

Alcohol and withdrawal: from animal research to clinical issues

21 January 2018

1 reference

Neurobiological substrates for the dark side of compulsivity in addiction

21 January 2018

1 reference

Pharmacological treatment of alcohol dependence: a review of the evidence

21 January 2018

1 reference

Effect of the threat of a disulfiram-ethanol reaction on cue reactivity in alcoholics

21 January 2018

1 reference

mechanisms of disulfiram-induced cocaine abstinence: antabuse and cocaine relapse

21 January 2018

1 reference

Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram

21 January 2018

1 reference

Experienced Acetaldehyde Reaction Does Not Improve Treatment Response in Outpatients Treated With Supervised Disulfiram

21 January 2018

1 reference

Status of disulfiram in present day alcoholic deaddiction therapy

21 January 2018

1 reference

Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders

21 January 2018

1 reference

A double-blind, placebo-controlled assessment of the safety of potential interactions between intravenous cocaine, ethanol, and oral disulfiram.

21 January 2018

1 reference

Estradiol valerate and alcohol intake: a comparison between Wistar and Lewis rats and the putative role of endorphins

21 January 2018

1 reference

Family history of alcoholism influences naltrexone-induced reduction in alcohol drinking.

21 January 2018

1 reference

Genetic basis for predicting response to naltrexone in the treatment of alcohol dependence

21 January 2018

1 reference

Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.

21 January 2018

1 reference

An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study

21 January 2018

1 reference

Advances in development of medications for alcoholism treatment

21 January 2018

1 reference

Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial

21 January 2018

1 reference

Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment.

21 January 2018

1 reference

The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking

21 January 2018

1 reference

Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?

21 January 2018

1 reference

Pharmacotherapy of dual substance abuse and dependence

21 January 2018

1 reference

Naltrexone decreases heavy drinking rates in smoking cessation treatment: an exploratory study

21 January 2018

1 reference

Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation

21 January 2018

1 reference

Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action

21 January 2018

1 reference

Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors

21 January 2018

1 reference

Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study

21 January 2018

1 reference

The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801.

21 January 2018

1 reference

Pharmacotherapy of alcohol dependence: a review of the clinical data

21 January 2018

1 reference

Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation

21 January 2018

1 reference

Acamprosate efficacy in alcohol-dependent patients: summary of results from three pivotal trials

21 January 2018

1 reference

The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis

21 January 2018

1 reference

Naltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBINE study.

21 January 2018

1 reference

Why is disulfiram superior to acamprosate in the routine clinical setting? A retrospective long-term study in 353 alcohol-dependent patients

21 January 2018

1 reference

A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence

21 January 2018

1 reference

An open randomized study comparing disulfiram and acamprosate in the treatment of alcohol dependence

21 January 2018

1 reference

Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review

21 January 2018

1 reference

Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study

21 January 2018

1 reference

Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres' experience with pharmacotherapy

21 January 2018

1 reference

Combined therapy: what does acamprosate and naltrexone combination tell us?

21 January 2018

1 reference

Gabapentin Combined With Naltrexone for the Treatment of Alcohol Dependence

21 January 2018

1 reference

Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study

21 January 2018

1 reference

Topiramate for the treatment of alcohol dependence: comparison with naltrexone

21 January 2018

1 reference

Individualised treatment in alcohol-dependent patients

21 January 2018

1 reference

A double-blind, randomized trial of sertraline for alcohol dependence: moderation by age of onset [corrected] and 5-hydroxytryptamine transporter-linked promoter region genotype

21 January 2018

1 reference

Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking

21 January 2018

1 reference

Prediction of serotonergic treatment efficacy using age of onset and Type A/B typologies of alcoholism

21 January 2018

1 reference

Genome-wide association and genetic functional studies identify autism susceptibility candidate 2 gene (AUTS2) in the regulation of alcohol consumption

21 January 2018

1 reference

Matching Alcoholism Treatments to Client Heterogeneity: Project MATCH posttreatment drinking outcomes

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ECP.12.31

1 reference

27 August 2017

1 reference